-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk announced the main findings of the STEP Young phase 3 clinical trial on November 16. The trial aims to evaluate the safety and efficacy of the study's maximum dose of 1.7 mg or 2.4 mg weekly simeglutide injections based on limiting caloric intake and increasing physical activity in obese children aged 6 to <12 years. Research results showed that Wegovy reduced the BMI of nearly 80% of obese children aged 6 to 12 by 10% or more, and 0% in the placebo group. According to Novo Nordisk, the overall safety and tolerability of simeglutide observed in the STEP Young study was consistent with the results of Novo's previous clinical trials of simeglutide in children and adults, and no unexpected safety issues were found. Furthermore, no safety issues related to child growth or puberty have been identified.
Share
Listen to the news
Novo Nordisk announced the main findings of the STEP Young phase 3 clinical trial on November 16. The trial aimed to evaluate the safety and efficacy of the study's maximum dose of 1.7 mg or 2.4 mg weekly simeglutide injections based on limiting caloric intake and increasing physical activity in obese children aged 6 to <12 years. Research results showed that Wegovy reduced the BMI of nearly 80% of obese children aged 6 to 12 by 10% or more, and 0% in the placebo group. According to Novo Nordisk, the overall safety and tolerability of simeglutide observed in the STEP Young study was consistent with the results of Novo's previous clinical trials of simeglutide in children and adults, and no unexpected safety issues were found. Furthermore, no safety issues related to child growth or puberty have been identified.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending